Partial-gland Cryoablation Outcomes for Localized Prostate Cancer in Patients with Magnetic Resonance Imaging (MRI)-visible and MRI-invisible Lesions

Siegel, 2022, Cancer statistics, 2022, CA Cancer J Clin, 72, 7, 10.3322/caac.21708 National Comprehensive Cancer Network, 2022 Eastham, 2022, Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management, J Urol, 208, 10, 10.1097/JU.0000000000002757 Chen, 2017, Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer, JAMA, 317, 1141, 10.1001/jama.2017.1652 Valerio, 2017, New and established technology in focal ablation of the prostate: a systematic review, Eur Urol, 71, 17, 10.1016/j.eururo.2016.08.044 Marra, 2018, Focal therapy in localised prostate cancer: real-world urological perspective explored in a cross-sectional European survey, Urol Oncol, 36, 529.e11, 10.1016/j.urolonc.2018.08.013 Kasivisvanathan, 2019, Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis, Eur Urol, 76, 284, 10.1016/j.eururo.2019.04.043 Lebastchi, 2020, Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus, Eur Urol, 78, 371, 10.1016/j.eururo.2020.05.018 Shah, 2019, Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry, Eur Urol, 76, 98, 10.1016/j.eururo.2018.12.030 Guillaumier, 2018, A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer, Eur Urol, 74, 422, 10.1016/j.eururo.2018.06.006 Bass, 2019, Oncologic and functional outcomes of partial gland ablation with high intensity focused ultrasound for localized prostate cancer, J Urol, 201, 113, 10.1016/j.juro.2018.07.040 Abreu, 2020, High intensity focused ultrasound hemigland ablation for prostate cancer: initial outcomes of a United States series, J Urol, 204, 741, 10.1097/JU.0000000000001126 Nahar, 2020, Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer, J Urol, 204, 483, 10.1097/JU.0000000000001015 Ehdaie, 2022, MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study, Lancet Oncol, 23, 910, 10.1016/S1470-2045(22)00251-0 Mortezavi, 2019, Extensive histological sampling following focal therapy of clinically significant prostate cancer with high intensity focused ultrasound, J Urol, 202, 717, 10.1097/JU.0000000000000298 Patel, 2018, The role of systematic and targeted biopsies in light of overlap on magnetic resonance imaging ultrasound fusion biopsy, Eur Urol Oncol, 1, 263, 10.1016/j.euo.2018.03.009 Brisbane, 2022, Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling, Eur Urol, 82, 303, 10.1016/j.eururo.2022.01.008 Basourakos, 2020, Feasibility of in-office MRI-targeted partial gland cryoablation for prostate cancer: an IDEAL stage 2A study. BMJ Surg Interv, Health Technol, 2, e000056 Le Nobin, 2015, Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis, J Urol, 194, 364, 10.1016/j.juro.2015.02.080 Priester, 2017, Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology, J Urol, 197, 320, 10.1016/j.juro.2016.07.084 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Weinstock, 2020, Development of treatments for localized prostate cancer in patients eligible for active surveillance: U.S. Food and Drug Administration Oncology Center of Excellence public workshop, J Urol, 203, 115, 10.1097/JU.0000000000000532 Le, 2015, Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology, Eur Urol, 67, 569, 10.1016/j.eururo.2014.08.079 Baskin, 2022, Medium term outcomes of focal cryoablation for intermediate and high risk prostate cancer: MRI and PSA are not predictive of residual or recurrent disease, Urol Oncol, 40, 451.e15, 10.1016/j.urolonc.2022.06.010 Oishi, 2019, Hemigland cryoablation of localized low, intermediate and high risk prostate cancer: oncologic and functional outcomes at 5 years, J Urol, 202, 1188, 10.1097/JU.0000000000000456 Klotz, 2021, Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer, J Urol, 205, 769, 10.1097/JU.0000000000001362 Tourinho-Barbosa, 2020, Focal therapy for localized prostate cancer with either high intensity focused ultrasound or cryoablation: a single institution experience, J Urol, 203, 320, 10.1097/JU.0000000000000506 Ahdoot, 2020, MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis, N Engl J Med, 382, 917, 10.1056/NEJMoa1910038 Al Hussein Al Awamlh, 2020, Prostate multiparametric magnetic resonance imaging features following partial gland cryoablation, Urology, 138, 98, 10.1016/j.urology.2020.01.005 Golan, 2018, Development of a nationally representative coordinated registry network for prostate ablation technologies, J Urol, 199, 1488, 10.1016/j.juro.2017.12.058